FrancophonIA/ELRC3.0 huggingface dataset:
English: The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients, the analysis of 240-week data from randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients and the analysis of 96-week data from randomised, double-blind, active-control trial (ONCEMRK, Protocol 292) in antiretroviral treatment-naïve HIV-1 infected adult patients.
Croatian: Dokazi djelotvornosti raltegravira temeljili su se na analizama podataka nakon 96 tjedana iz dva randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja (BENCHMRK 1 i BENCHMRK 2, protokoli 018 i 019) u odraslih bolesnika inficiranih virusom HIV-1 koji su prethodno liječeni antiretrovirusnim lijekovima, na analizi podataka prikupljenih nakon 240 tjedana randomiziranog, dvostruko slijepog, aktivnim lijekom kontroliranog kliničkog ispitivanja (STARTMRK, Protokol 021) u odraslih bolesnika inficiranih virusom HIV-1 koji prethodno nisu bili liječeni antiretrovirusnim lijekovima te na analizi podataka prikupljenih nakon 96 tjedana iz randomiziranog, dvostruko slijepog, aktivnim lijekom kontroliranog ispitivanja (ONCEMRK, Protokol 292) u odraslih bolesnika inficiranih virusom HIV-1 koji prethodno nisu bili liječeni antiretrovirusnim lijekovima.
English: 100 mg chewable tablets: Each chewable tablet contains 100 mg of raltegravir (as potassium).
Croatian: Tableta za žvakanje od 100 mg: Jedna tableta za žvakanje sadrži 100 mg raltegravira (u obliku raltegravirkalija).
English: Uncommon erectile dysfunction, gynaecomastia, menopausal symptoms
Croatian: Poremećaji reproduktivnog sustava i dojki manje često erektilna disfunkcija, ginekomastija, simptomi menopauze
English: Pale orange coloured, oval shaped, chewable tablet scored on both sides with the MSD corporate logo and "477" on one side and without inscription on the other side.
Croatian: Blijedonarančasta, ovalna tableta za žvakanje, s razdjelnom crtom na obje strane te s logotipom tvrtke MSD i oznakom "477" na jednoj i bez oznaka na drugoj strani.
English: No dose adjustment required for raltegravir.
Croatian: Nije potrebno prilagođavati dozu raltegravira.
English: 300 mg twice daily
Croatian: 300 mg dvaput na dan
English: Infants and toddlers 4 weeks to less than 2 years of age Raltegravir twice daily has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to less than 2 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Croatian: Dojenčad i mala djeca u dobi od 4 tjedna do manje od 2 godine Raltegravir dvaput na dan je, u kombinaciji s drugim antiretrovirusnim lijekovima u ispitivanju IMPAACT P1066, ispitan i u 26 dojenčadi i male djece u dobi od 4 tjedna do manje od 2 godine inficirane virusom HIV-1 (vidjeti dijelove 5.1 i 5.2).
English: aluminium/magnesium hydroxide antacid (raltegravir 1,200 mg single dose)
Croatian: antacid s aluminijevim i magnezijevim hidroksidom (raltegravir jednokratna doza od 1200 mg)
English: For patients weighing between 11 and 20 kg, either the chewable tablet or oral suspension can be used, as specified in Table 2.
Croatian: Za bolesnike tjelesne težine između 11 i 20 kg može se upotrijebiti ili tableta za žvakanje ili oralna suspenzija, kako je prikazano u Tablici 2. Bolesnici mogu nastaviti primati oralnu suspenziju dokle god im je tjelesna težina manja od 20 kg.
English: No dose adjustment required for raltegravir or boceprevir.
Croatian: Nije potrebno prilagođavati dozu raltegravira ili boceprevira.
English: Results of Week 48 and 96 analyses
Croatian: Rezultati analiza 48. i 96. tjedna
English: At the NOAEL, systemic exposure was similar to that at the clinical dose of 1,200 mg once daily.
Croatian: Kod primjene najviše doze koja ne uzrokuje štetne učinke (NOAEL) sustavna izloženost bila je slična onoj koja se postiže kliničkom dozom od 1200 mg jedanput na dan.
English: Strong inducers of drug metabolizing enzymes (e.g., rifampicin) have not been studied with raltegravir 1,200 mg once daily, but could result in decreased raltegravir trough plasma levels; therefore, co-administration with raltegravir 1,200 mg once daily is not recommended.
Croatian: Nije ispitivana istodobna primjena snažnih induktora enzima koji sudjeluju u metabolizmu lijekova (npr. rifampicina) s raltegravirom u dozi od 1200 mg jedanput na dan, no ona bi mogla sniziti najniže koncentracije raltegravira u plazmi.
English: Table 4 Efficacy Outcome at Weeks 48 and 96
Croatian: Tablica 4 Ishod djelotvornosti u 48. i 96. tjednu
English: Rinse with water and air dry.
Croatian: Isperite ih vodom i ostavite da se osuše na zraku.
English: At the NOAEL, systemic exposure was similar to that at the clinical dose of 400 mg twice daily.
Croatian: Kod primjene najviše doze koja ne uzrokuje štetne učinke (NOAEL) sustavna izloženost bila je slična onoj koja se postiže kliničkom dozom od 400 mg dvaput na dan.
English: No dose adjustment required for raltegravir (400 mg twice daily).
Croatian: Nije potrebno prilagođavati dozu raltegravira (400 mg dvaput na dan).
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 1,200 mg once daily and the group receiving raltegravir 400 mg twice daily.
Croatian: Demografska obilježja (spol, dob i rasa) i početne karakteristike bolesnika u skupini koja je primala raltegravir u dozi od 1200 mg jedanput na dan bili su usporedivi s onima u bolesnika koji su primali raltegravir u dozi od 400 mg dvaput na dan.
English: BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimised background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Croatian: U ispitivanjima BENCHMRK 1 i BENCHMRK 2 (multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja) ocjenjivale su se sigurnost i antiretrovirusna aktivnost raltegravira u dozi od 400 mg dvaput na dan naspram placeba, u kombinaciji s optimiziranom osnovnom terapijom (OBT), u bolesnika zaraženih HIV-om u dobi od 16 ili više godina, a u kojih je dokumentirana rezistencija na barem 1 lijek iz svake od 3 skupine antiretrovirusnih lijekova (NRTI, NNRTI, PI).
English: Body weight Formulation
Croatian: Tjelesna težina Oblik lijeka
English: 25 to less than 28
Croatian: Broj tableta za žvakanje od 25 do manje od 28
English: ), median [range] CD4 percent, median [range] HIV-1 RNA >100,000 copies/mL CDC HIV category B or C Prior ART Use by Class NNRTI NRTI PI Response
Croatian: ), medijan [raspon] Postotak CD4 stanica, medijan [raspon] HIV-1 RNK > 100 000 kopija/ml CDC HIV kategorija B ili C Prethodna primjena ART-a, prema skupinama NNRTI IP Odgovor
English: Isentress is also available in a 400 mg tablet, a 600 mg tablet and in a chewable tablet.
Croatian: Isentress je dostupan i u obliku tableta od 400 mg, tableta od 600 mg te tableta za žvakanje.
English: What Isentress looks like and contents of the pack The film-coated tablet is oval-shaped, pink, marked with "227" on one side.
Croatian: Filmom obložena tableta je ovalna, ružičasta, s oznakom "227" na jednoj strani.
English: Weight based dosing, see dosing Table 1 19 *Number of patients with intensive pharmacokinetic (PK) results at the final recommended dose.
Croatian: od 3 do manje od 20 kg oralna suspenzija doziranje na temelju tjelesne težine, vidjeti Tablicu 1 *Broj bolesnika s intenzivnim farmakokinetičkim (PK) rezultatima pri konačnoj preporučenoj dozi.
English: No dose adjustment required for raltegravir or methadone.
Croatian: Nije potrebno prilagođavati dozu raltegravira ili metadona.
English: SEDATIVE midazolam (raltegravir 400 mg Twice Daily)
Croatian: SEDATIV midazolam (raltegravir 400 mg dvaput na dan)
English: ≥ 25 kg Chewable tablet
Croatian: ≥ 25 kg filmom obložena tableta
English: The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients and the analysis of 240-week data from randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients.
Croatian: Dokazi djelotvornosti raltegravira temeljili su se na analizama podataka nakon 96 tjedana iz dva randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja (BENCHMRK 1 i BENCHMRK 2, protokoli 018 i 019) u odraslih bolesnika inficiranih virusom HIV-1 koji su prethodno liječeni antiretrovirusnim lijekovima te na analizi podataka prikupljenih nakon 240 tjedana randomiziranog, dvostruko slijepog, aktivnim lijekom kontroliranog kliničkog ispitivanja (STARTMRK, Protokol 021) u odraslih bolesnika inficiranih virusom HIV-1 koji prethodno nisu bili liječeni antiretrovirusnim lijekovima.
English: The 100 mg chewable tablet can be split into equal halves if necessary; however, breaking the tablets should be avoided.
Croatian: Tableta za žvakanje od 100 mg može se po potrebi podijeliti na jednake polovice.
English: raltegravir AUC  72% raltegravir C24 hr  48% raltegravir Cmax  74%
Croatian: raltegravir AUC  72% raltegravir C24h  48% raltegravir Cmax  74%
English: Table 2 Efficacy Outcome at Weeks 48 and 96
Croatian: Tablica 2 Ishod djelotvornosti 48. i 96. tjedna
English: Unit dose sachet for ISENTRESS 100 mg granules for oral suspension - foil sachet
Croatian: Jednodozne vrećice ISENTRESS 100 mg granule za oralnu suspenziju - folija vrećice
English: A slight increase in incidence of supernumerary ribs, a variant in the normal developmental process, was observed in rat foetuses of dams exposed to raltegravir at approximately 4.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr. No development effects were seen at 3.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr.
Croatian: Zapažen je neznatan porast incidencije prekobrojnih rebara, različito od normalnog razvojnog procesa, kod fetusa štakora, kada je izloženost ženke raltegraviru bila približno 4,4 puta veća od izloženosti u ljudi pri dozi od 400 mg dvaput na dan izračunate na temelju AUC0-24h.
English: The use of ISENTRESS is not recommended in pre-term neonates.
Croatian: Primjena lijeka ISENTRESS ne preporučuje se u nedonoščadi.
English: 0.5 mL (5 mg) once daily
Croatian: 0,5 ml (5 mg) jedanput na dan od 4 do manje od 5
English: Throw away any leftover Isentress after you have given the dose to your child.
Croatian: Nakon što djetetu date dozu, bacite svu preostalu količinu lijeka Isentress.
English: etravirine AUC  10% etravirine C12hr  17% etravirine Cmax  4%
Croatian: etravirin AUC  10% etravirin C12h  17% etravirin Cmax  4%
English: Raltegravir twice daily has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 to 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Croatian: Raltegravir dvaput na dan je, u kombinaciji s drugim antiretrovirusnim lijekovima u ispitivanju IMPAACT P1066, ispitan u 126 djece i adolescenata u dobi od 2 do 18 godina inficiranih virusom HIV-1 koji su prethodno primali antiretrovirusnu terapiju (vidjeti dijelove 5.1 i 5.2).
English: Raltegravir has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 to 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Croatian: Raltegravir je, u kombinaciji s drugim antiretrovirusnim lijekovima u ispitivanju IMPAACT P1066, ispitan u 126 djece i adolescenata u dobi od 2 do 18 godina inficiranih virusom HIV-1 koji su prethodno primali antiretrovirusnu terapiju (vidjeti dijelove 5.1 i 5.2).
English: Table 5 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
Croatian: Tablici 5 prikazani su farmakokinetički parametri kod primjene tablete od 400 mg, tablete za žvakanje i granula za oralnu suspenziju, prema tjelesnoj težini.
English: raltegravir AUC  67% raltegravir C24hr  26% raltegravir Cmax  16%
Croatian: raltegravir AUC  67% raltegravir C24h  26% raltegravir Cmax  16%
English: 2 x 100 mg twice daily
Croatian: 2 x 100 mg dvaput na dan najmanje 40
English: 12 hours after raltegravir raltegravir AUC  14% raltegravir C24 hr  58% raltegravir Cmax  14%
Croatian: 12 sati nakon raltegravira raltegravir AUC  14% raltegravir C24h  58% raltegravir Cmax  14%
English: Infants and toddlers 4 weeks to less than 2 years of age Raltegravir has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to less than 2 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Croatian: Dojenčad i mala djeca u dobi od 4 tjedna do manje od 2 godine Raltegravir je, u kombinaciji s drugim antiretrovirusnim lijekovima u ispitivanju IMPAACT P1066, ispitan i u 26 dojenčadi i male djece u dobi od 4 tjedna do manje od 2 godine inficirane virusom HIV-1 (vidjeti dijelove 5.1 i 5.2).
English: Driving and using machines Do not operate machines, drive or cycle if you feel dizzy after taking this medicine.
Croatian: Ako nakon uzimanja ovog lijeka osjetite omaglicu, nemojte raditi sa strojevima niti upravljati vozilom ili biciklom.
English: What Isentress looks like and contents of the pack The 600 mg film-coated tablet is oval-shaped, yellow, marked with MSD corporate logo and "242" on one side and plain on the other side.
Croatian: Filmom obložena tableta od 600 mg je ovalna, žuta, s logotipom tvrtke MSD i oznakom "242" na jednoj strani te bez oznaka na drugoj strani.
English: etravirine (raltegravir 400 mg Twice Daily)
Croatian: etravirin (raltegravir 400 mg dvaput na dan)
English: Bottle for ISENTRESS 400 mg film-coated tablets
Croatian: Boca za ISENTRESS 400 mg filmom obložene tablete
English: High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure, induction seal and silica gel dessicant.
Croatian: Boca od polietilena visoke gustoće (HDPE) s polipropilenskim sigurnosnim zatvaračem za djecu, zatvorena zalijepljenom zaštitnom folijom, koja sadrži silika gel kao sredstvo za sušenje.
English: Contact your doctor, pharmacist or nurse immediately if you experience unexplained muscle pain, tenderness, or weakness while taking this medicine.
Croatian: Ako tijekom uzimanja ovog lijeka osjetite bol, osjetljivost ili slabost u mišićima nepoznatog uzroka, odmah se javite liječniku, ljekarniku ili medicinskoj sestri.
English: Bottle for ISENTRESS 600 mg film-coated tablets
Croatian: Boca za ISENTRESS 600 mg filmom obložene tablete
English: The SWITCHMRK 1 & 2 (Protocols 032 & 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA < 50 copies/mL; stable regimen > 3 months) therapy with lopinavir 200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomised them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively).
Croatian: Ispitivanja SWITCHMRK 1 i 2 (Protokoli 032 i 033) provedena su u bolesnika inficiranih HIV-om koji su primali supresivnu terapiju (na probiru < 50 HIV-RNK kopija/ml; stabilni režim > 3 mjeseca) lopinavirom 200 mg (+) ritonavirom 50 mg, 2 tablete dvaput na dan, uz najmanje dva nukleozidna inhibitora reverzne transkriptaze.
English: 2 hours before raltegravir raltegravir AUC  51% raltegravir C12 hr  56% raltegravir Cmax  51%
Croatian: 2 sata prije raltegravira raltegravir AUC  51% raltegravir C12h  56% raltegravir Cmax  51%
English: Switch to raltegravir (400 mg twice daily)
Croatian: Prelazak na raltegravir (400 mg dvaput na dan)
English: ≤ 100,000 copies/mL CD4 count ≤ 200 cells/mm > 200 cells/mm Viral Subtype Clade B Non-Clade B 233 (205, 261)
Croatian: Početne karakteristike HIV-RNK > 100 000 kopija/ml ≤ 100,000 kopija /ml Broj CD4 stanica ≤ 200 stanica/mm > 200 stanica/mm Podtip virusa skupine B Podtipovi virusa osim skupine B 233 (205, 261)
English: raltegravir AUC  14% raltegravir C24hr  6% raltegravir Cmax  9%
Croatian: raltegravir AUC  14% raltegravir C24h  6% raltegravir Cmax  9%
English: ISENTRESS 100 mg chewable tablets
Croatian: ISENTRESS 100 mg tablete za žvakanje
English: Treatment-naïve adult patients (1,200 mg [2 x 600 mg] once daily) ONCEMRK (multi-centre, randomised, double-blind, active-control trial; Protocol 292) evaluated the safety and anti-retroviral activity of raltegravir 1,200 mg once daily + emtricitabine (+) tenofovir disoproxil fumarate vs. raltegravir 400 mg twice daily, in combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-naïve HIV-infected patients with HIV RNA > 1,000 copies/mL.
Croatian: U ispitivanju ONCEMRK (multicentrično, randomizirano, dvostruko slijepo, aktivnim lijekom kontrolirano ispitivanje; Protokol 292) ocjenjivale su se sigurnost i antiretrovirusna aktivnost raltegravira u dozi od 1200 mg jedanput na dan + emtricitabin (+) tenofovirdizoproksilfumarat naspram raltegravira u dozi od 400 mg dvaput na dan u kombinaciji s emtricitabinom (+) tenofovirdizoproksilfumaratom u bolesnika s HIV infekcijom s > 1000 HIV-RNK kopija/ml koji prethodno nisu bili liječeni.
English: MSD Pharma Hungary Kft. Tel.: +36 1 888 53 00 hungary_msd@merck.com
Croatian: Tel.: +36 1 888 53 00 hungary_msd@merck.com
English: Table 8 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
Croatian: Tablici 8 prikazani su farmakokinetički parametri kod primjene tablete od 400 mg, tablete za žvakanje i granula za oralnu suspenziju, prema tjelesnoj težini.
English: ISENTRESS 25 mg chewable tablets raltegravir
Croatian: ISENTRESS 25 mg tablete za žvakanje raltegravir
English: Uncommon acne, alopecia, dermatitis acneiforme, dry skin, erythema, facial wasting, hyperhidrosis, lipoatrophy, lipodystrophy acquired, lipohypertrophy, night sweats, prurigo, pruritus, pruritus generalised, rash macular, rash maculopapular, rash pruritic, skin lesion, urticaria, xeroderma, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)
Croatian: Poremećaji kože i potkožnog tkiva često osip manje često akne, alopecija, akneiformni dermatitis, suha koža, eritem, gubitak potkožnog masnog tkiva s lica, hiperhidroza, lipoatrofija, stečena lipodistrofija, lipohipertrofija, noćno znojenje, prurigo, pruritus, generalizirani pruritus, makularni osip, makulopapularni osip, osip s pruritusom, kožne lezije, urtikarija, kseroderma, Stevens-Johnsonov sindrom, osip izazvan lijekom uz eozinofiliju i sustavne simptome (DRESS)
English: Uncommon anaemia, iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia, thrombocytopenia
Croatian: Poremećaji krvi i limfnog sustava manje često anemija, sideropenična anemija, bol u limfnom čvoru, limfadenopatija, neutropenija, trombocitopenija
English: Carton for 100 mg chewable tablets
Croatian: Kutija za 100 mg tablete za žvakanje
English: Chewable tablet 100 mg
Croatian: Tableta za žvakanje od 100 mg
English: raltegravir AUC  37% raltegravir C12hr  28% raltegravir Cmax  33%
Croatian: raltegravir AUC  37% raltegravir C12h  28% raltegravir Cmax  33%
English: Rhabdomyolysis was an uncommonly reported serious adverse reaction in post-marketing use of raltegravir 400 mg twice daily.
Croatian: Manje često prijavljivana ozbiljna nuspojava nakon stavljanja u promet raltegravira u dozi od 400 mg dvaput na dan bila je rabdomioliza.
English: - Crospovidone, Type A - Sodium stearyl fumarate - Magnesium stearate - Hypromellose 2910/6cP - Macrogol/PEG 400 - Ethylcellulose 20 cP - Ammonium hydroxide - Medium chain triglycerides - Oleic acid - Yellow iron oxide
Croatian: A - natrijev stearilfumarat - magnezijev stearat - hipromeloza 2910/6cP - makrogol/PEG 400 - etilceluloza 20 cP - amonijev hidroksid - trigliceridi srednje duljine lanca - oleatna kiselina - željezov oksid, žuti
English: The other ingredients are: hydroxypropyl cellulose, sucralose, saccharin sodium , sodium citrate dihydrate, mannitol, red iron oxide, yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E420), fructose, natural and artificial flavours (orange, banana, and masking), aspartame (E951), crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
Croatian: Drugi sastojci su: hidroksipropilceluloza, sukraloza, saharinnatrij, natrijev citrat dihidrat, manitol, crveni željezov oksid, žuti željezov oksid, amonijev glicirizat, sorbitol (E420), fruktoza, prirodne i umjetne arome (naranča, banana i aroma za maskiranje okusa), aspartam (E951), krospovidon tipa A, magnezijev stearat, natrijev stearilfumarat, etilceluloza 20 cP, amonijev hidroksid, trigliceridi srednje duljine lanca, oleatna kiselina, hipromeloza 2910/6cP i makrogol/PEG 400.
English: Table 6 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
Croatian: U Tablici 6 prikazani su farmakokinetički parametri kod primjene tablete od 400 mg, tablete za žvakanje i granula za oralnu suspenziju, prema tjelesnoj težini.
English: raltegravir AUC ↑ 37 % raltegravir C12 hr ↑ 24 % raltegravir Cmax ↑ 51 %
Croatian: raltegravir AUC ↑ 37% raltegravir C12h ↑ 24% raltegravir Cmax ↑ 51%
English: No dosage adjustment required for raltegravir or midazolam.
Croatian: Nije potrebno prilagođavati dozu raltegravira ili midazolama.
English: 6 hours after raltegravir raltegravir AUC  11% raltegravir C12 hr  49% raltegravir Cmax  10%
Croatian: 6 sati nakon raltegravira raltegravir AUC  11% raltegravir C12h  49% raltegravir Cmax  10%
English: raltegravir AUC  41% raltegravir C12hr  77% raltegravir Cmax  24%
Croatian: raltegravir AUC  41% raltegravir C12h  77% raltegravir Cmax  24%
English: Recommendations concerning co-administration calcium carbonate antacid (raltegravir 1,200 mg single dose)
Croatian: antacid s kalcijevim karbonatom (raltegravir jednokratna doza od 1200 mg)
English: The other ingredients are: hydroxypropyl cellulose, sucralose, mannitol, monoammonium glycyrrhizinate, sorbitol (E420), fructose, banana flavour, sucrose, crospovidone Type A, magnesium stearate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP, macrogol/PEG 400, microcrystalline cellulose and carmellose sodium.
Croatian: Drugi sastojci su: hidroksipropilceluloza, sukraloza, manitol, amonijev glicirizat, sorbitol (E420), fruktoza, aroma banane, saharoza, krospovidon tipa A, magnezijev stearat, etilceluloza 20 cP, amonijev hidroksid, trigliceridi srednje duljine lanca, oleatna kiselina, hipromeloza 2910/6cP, makrogol/PEG 400, mikrokristalična celuloza i umrežena karmelozanatrij.